Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Biliary Tract Diseases

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 141 articles:
HTML format
Text format



Single Articles


    December 2018
  1. HUANG L, Cai J, Guo H, Gu J, et al
    ID3 Promotes Stem Cell Features and Predicts Chemotherapeutic Response of Intrahepatic Cholangiocarcinoma.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30404.
    PubMed     Text format     Abstract available


  2. KHAMBU B, Li T, Yan S, Yu C, et al
    Hepatic Autophagy Deficiency Compromises FXR Functionality and Causes Cholestatic Injury.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30407.
    PubMed     Text format     Abstract available


  3. WANG F, Wang J, Li Y, Yuan J, et al
    Gallstone disease and type 2 diabetes risk: A Mendelian randomization study.
    Hepatology. 2018 Dec 4. doi: 10.1002/hep.30403.
    PubMed     Text format     Abstract available


  4. DE JONG IEM, Matton APM, van Praagh JB, van Haaften WT, et al
    Peribiliary glands are key in regeneration of the human biliary epithelium after severe bile duct injury.
    Hepatology. 2018 Dec 2. doi: 10.1002/hep.30365.
    PubMed     Text format     Abstract available


    November 2018
  5. SANTAMARIA E, Rodriguez-Ortigosa CM, Uriarte I, Latasa MU, et al
    The epidermal growth factor receptor ligand amphiregulin protects from cholestatic liver injury and regulates bile acids synthesis.
    Hepatology. 2018 Nov 8. doi: 10.1002/hep.30348.
    PubMed     Text format     Abstract available


  6. TIRNITZ-PARKER JEE, Forbes SJ, Olynyk JK, Ramm GA, et al
    Cellular plasticity in liver regeneration - spotlight on cholangiocytes.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30340.
    PubMed     Text format     Abstract available


    October 2018
  7. CASTRO NARRO GE, Gamboa Dominguez A, Consuelo Sanchez A, Salazar Martinez A, et al
    Combined Hepatocellular-Cholangiocarcinoma in a Patient with Cirrhosis due to Cholesteryl Ester Storage Disease.
    Hepatology. 2018 Oct 29. doi: 10.1002/hep.30331.
    PubMed     Text format     Abstract available


  8. BANALES JM, Inarrairaegui M, Arbelaiz A, Milkiewicz P, et al
    Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis.
    Hepatology. 2018 Oct 16. doi: 10.1002/hep.30319.
    PubMed     Text format     Abstract available


  9. GELLERT-KRISTENSEN H, Dalila N, Nielsen SF, Nordestgaard BG, et al
    Identification and replication of six new loci associated with gallstone disease.
    Hepatology. 2018 Oct 16. doi: 10.1002/hep.30313.
    PubMed     Text format     Abstract available


  10. ANEZ-BUSTILLOS L, Dao DT, Potemkin AK, Perez-Atayde AR, et al
    An Intravenous Fish Oil Based Lipid Emulsion successfully treats intractable pruritus and cholestasis in a patient with MVID.
    Hepatology. 2018 Oct 12. doi: 10.1002/hep.30311.
    PubMed     Text format     Abstract available


  11. MANSINI AP, Peixoto E, Jin S, Richard S, et al
    The chemosensory function of primary cilia regulates cholangiocyte migration, invasion and tumor growth.
    Hepatology. 2018 Oct 9. doi: 10.1002/hep.30308.
    PubMed     Text format     Abstract available


  12. PERUGORRIA MJ, Olaizola P, Banales JM
    Cholangiocyte-to-Hepatocyte Differentiation: a Context Dependent Process and an Opportunity for Regenerative Medicine.
    Hepatology. 2018 Oct 8. doi: 10.1002/hep.30305.
    PubMed     Text format     Abstract available


    September 2018
  13. SIRICA AE, Gores GJ, Groopman JD, Selaru FM, et al
    Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.
    Hepatology. 2018 Sep 25. doi: 10.1002/hep.30289.
    PubMed     Text format     Abstract available


  14. CAI SY, Boyer JL
    Bile Infarcts - new insights into the pathogenesis of obstructive cholestasis.
    Hepatology. 2018 Sep 25. doi: 10.1002/hep.30291.
    PubMed     Text format     Abstract available


  15. BLOKKER BA, Maijo M, Echeandia M, Galduroz M, et al
    Fine-tuning of SIRT1 expression is essential to protect the liver from cholestatic liver disease.
    Hepatology. 2018 Sep 19. doi: 10.1002/hep.30275.
    PubMed     Text format     Abstract available


  16. RUSSELL JO, Lu WY, Okabe H, Abrams M, et al
    Hepatocyte-specific beta-catenin deletion during severe liver injury provokes cholangiocytes to differentiate into hepatocytes.
    Hepatology. 2018 Sep 14. doi: 10.1002/hep.30270.
    PubMed     Text format     Abstract available


  17. KAMATH B, Mack CL
    From hepatocyte to cholangiocyte: the remarkable potential of transdifferentiation to treat cholestatic diseases.
    Hepatology. 2018 Sep 4. doi: 10.1002/hep.30250.
    PubMed     Text format     Abstract available


    August 2018
  18. MUIR AJ, Levy C, Janssen HLA, Montano-Loza AJ, et al
    Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.
    Hepatology. 2018 Aug 28. doi: 10.1002/hep.30237.
    PubMed     Text format     Abstract available


  19. YANG L, Zhou Y, Xu PP, Mourya R, et al
    Diagnostic Accuracy of Serum Matrix Metalloproteinase-7 for Biliary Atresia.
    Hepatology. 2018 Aug 28. doi: 10.1002/hep.30234.
    PubMed     Text format     Abstract available


  20. FRANCA A, Filho ACML, Guerra MT, Weerachayaphorn J, et al
    Effects of endotoxin on type 3 inositol 1,4,5-trisphosphate receptor in human cholangiocytes.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30228.
    PubMed     Text format     Abstract available


  21. CARPINO G, Cardinale V, Folseraas T, Overi D, et al
    Neoplastic transformation of peribiliary stem cell niche in cholangiocarcinoma arisen in primary sclerosing cholangitis.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30210.
    PubMed     Text format     Abstract available


  22. GHALLAB A, Hofmann U, Sezgin S, Vartak N, et al
    Bile micro-infarcts in cholestasis are initiated by rupture of the apical hepatocyte membrane and cause shunting of bile to sinusoidal blood.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30213.
    PubMed     Text format     Abstract available


  23. GORGIS NM, Kennedy C, Lam F, Thompson K, et al
    Clinical Consequences of Cardiomyopathy in Children with Biliary Atresia Requiring Liver Transplantation.
    Hepatology. 2018 Aug 3. doi: 10.1002/hep.30204.
    PubMed     Text format     Abstract available


  24. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30145.
    PubMed     Text format     Abstract available


  25. LAMBERTI D, Cristinziano G, Porru M, Leonetti C, et al
    HSP90 inhibition drives degradation of FGFR2 fusion proteins: implications for treatment of cholangiocarcinoma.
    Hepatology. 2018 Aug 1. doi: 10.1002/hep.30127.
    PubMed     Text format     Abstract available


    July 2018
  26. LOOMES KM, Spino C, Goodrich NP, Hangartner TN, et al
    Bone Density in Children with Chronic Liver Disease Correlates with Growth and Cholestasis.
    Hepatology. 2018 Jul 31. doi: 10.1002/hep.30196.
    PubMed     Text format     Abstract available


  27. OGAWA K, Kamimura K, Terai S
    Anti-Programmed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis.
    Hepatology. 2018 Jul 23. doi: 10.1002/hep.30189.
    PubMed     Text format     Abstract available


  28. SAYINER M, Golabi P, Stepanova M, Younossi I, et al
    Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Utilization.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30174.
    PubMed     Text format     Abstract available


    May 2018
  29. KHANNA A, Jopson L, Howel D, Bryant A, et al
    Rituximab is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A phase-2 Randomised Controlled Trial.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30099.
    PubMed     Text format     Abstract available


  30. LIAN M, Wang Q, Jiang X, Zhang J, et al
    The Immunobiology of RANKL and Myeloid Derived Suppressor Cell Activation in IgG4-related Sclerosing Cholangitis.
    Hepatology. 2018 May 18. doi: 10.1002/hep.30095.
    PubMed     Text format     Abstract available


  31. EATON JE, Vesterhus M, McCauley BM, Atkinson EJ, et al
    Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes in PSC: A Derivation & Validation Study Using Machine Learning.
    Hepatology. 2018 May 9. doi: 10.1002/hep.30085.
    PubMed     Text format     Abstract available


  32. TAYLOR SA, Green RM
    Bile acids, microbiota and metabolism.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30078.
    PubMed     Text format    


    April 2018
  33. RIZVI S, Gores GJ
    Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking through a Door Half-opened.
    Hepatology. 2018 Apr 27. doi: 10.1002/hep.30069.
    PubMed     Text format    


  34. TAYLOR AE, Carey AN, Kudira R, Lages CS, et al
    Interleukin 2 promotes hepatic regulatory T cell responses and protects from biliary fibrosis in murine sclerosing cholangitis.
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30061.
    PubMed     Text format     Abstract available


  35. BEDNAREK J, Traxinger B, Brigham D, Roach J, et al
    Cytokine-producing B cells promote immune-mediated bile duct injury in murine biliary atresia.
    Hepatology. 2018 Apr 20. doi: 10.1002/hep.30051.
    PubMed     Text format     Abstract available


  36. KONG B, Sun R, Huang M, Chow MD, et al
    A Novel Fibroblast Growth Factor 15 Dependent- and Bile Acid Independent-Promotion of Liver Regeneration in Mice.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30041.
    PubMed     Text format     Abstract available


    March 2018
  37. BEZERRA JA, Wells RG, Mack CL, Karpen SJ, et al
    BILIARY ATRESIA: Clinical and Research Challenges for the 21(st) Century.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29905.
    PubMed     Text format     Abstract available


  38. HOFMANN AF, Marschall HU
    Plasma Bile Acid Concentrations in Humans: Suggestions for Presentation in Tabular Form.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29909.
    PubMed     Text format    


  39. SOUFI N, Kohli R
    What's cold got to do with it? Cold induced thermogenesis and microbiome modification maybe regulated by bile acid physiology.
    Hepatology. 2018 Mar 30. doi: 10.1002/hep.29899.
    PubMed     Text format    


  40. KENNEDY L, Hargrove L, Demieville J, Karstens A, et al
    Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2(-/-) mice and human cholangiocarcinoma tumorigenesis.
    Hepatology. 2018 Mar 30. doi: 10.1002/hep.29898.
    PubMed     Text format     Abstract available


  41. PONSIOEN CY, Lindor KD, Mehta R, Dimick-Santos L, et al
    Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis.
    Hepatology. 2018 Mar 25. doi: 10.1002/hep.29882.
    PubMed     Text format     Abstract available


  42. SLIJEPCEVIC D, Roscam Abbing RLP, Fuchs CD, Haazen LCM, et al
    NTCP inhibition has hepatoprotective effects in cholestasis in mice.
    Hepatology. 2018 Mar 24. doi: 10.1002/hep.29888.
    PubMed     Text format     Abstract available


    February 2018
  43. PATHAK P, Cen X, Nichols RG, Ferrell JM, et al
    Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
    Hepatology. 2018 Feb 27. doi: 10.1002/hep.29857.
    PubMed     Text format     Abstract available


  44. WU JF, Lee CS, Lin WH, Jeng YM, et al
    Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy.
    Hepatology. 2018 Feb 27. doi: 10.1002/hep.29856.
    PubMed     Text format     Abstract available


  45. LI X, Liu R, Huang Z, Gurley EC, et al
    Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and human.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29838.
    PubMed     Text format     Abstract available


  46. MANSINI AP, Lorenzo Pisarello MJ, Thelen KM, Cruz-Reyes M, et al
    MiR-433 and miR-22 dysregulations induce HDAC6 overexpression and ciliary loss in cholangiocarcinoma.
    Hepatology. 2018 Feb 6. doi: 10.1002/hep.29832.
    PubMed     Text format     Abstract available


  47. OLAIZOLA P, Perugorria MJ, Banales JM
    Towards Personalized Medicine for Intrahepatic Cholangiocarcinoma: Pharmacogenomic Stratification of Patients.
    Hepatology. 2018 Feb 2. doi: 10.1002/hep.29830.
    PubMed     Text format    


    January 2018
  48. LI Q, Dutta A, Kresge C, Bugde A, et al
    Bile acids stimulate cholangiocyte fluid secretion by activation of membraneTMEM16A Cl(-) channels.
    Hepatology. 2018 Jan 23. doi: 10.1002/hep.29804.
    PubMed     Text format     Abstract available


  49. BRUNT E, Aishima S, Clavien PA, Fowler K, et al
    cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.
    Hepatology. 2018 Jan 23. doi: 10.1002/hep.29789.
    PubMed     Text format     Abstract available


  50. GULAMHUSEIN AF, Lazaridis KN
    Primary Biliary Cholangitis, DNA and Beyond: The Relative Contribution of Genes.
    Hepatology. 2018 Jan 13. doi: 10.1002/hep.29783.
    PubMed     Text format    


  51. ARNDTZ K, Hirschfield GM
    Quality of life and primary sclerosing cholangitis: the business of defining what counts.
    Hepatology. 2018 Jan 9. doi: 10.1002/hep.29775.
    PubMed     Text format    


    December 2017
  52. NEPAL C, O'Rourke CJ, Oliveira DV, Taranta A, et al
    Genomic Perturbations Reveal Distinct Regulatory Networks in Intrahepatic Cholangiocarcinoma.
    Hepatology. 2017 Dec 26. doi: 10.1002/hep.29764.
    PubMed     Text format     Abstract available


  53. BAJAJ JS, Hylemon PB
    Gut-Liver Axis Alterations in Alcoholic Liver Disease: Are Bile Acids the Answer?
    Hepatology. 2017 Dec 22. doi: 10.1002/hep.29760.
    PubMed     Text format    


  54. SO J, Khaliq M, Evason K, Ninov N, et al
    Wnt/beta-catenin signaling controls intrahepatic biliary network formation in zebrafish by regulating Notch activity.
    Hepatology. 2017 Dec 21. doi: 10.1002/hep.29752.
    PubMed     Text format     Abstract available


  55. ALI AH, Tabibian JH, Naser-Ghodsi N, Lennon RJ, et al
    Surveillance for Hepatobiliary Cancers in Patients with Primary Sclerosing Cholangitis.
    Hepatology. 2017 Dec 15. doi: 10.1002/hep.29730.
    PubMed     Text format     Abstract available


  56. LEVY C
    Evolving role of Obeticholic acid in primary biliary cholangitis.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29726.
    PubMed     Text format    


  57. MURILLO PEREZ F, Goet JC, Lammers WJ, Gulamhusein A, et al
    Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.
    Hepatology. 2017 Dec 8. doi: 10.1002/hep.29717.
    PubMed     Text format     Abstract available


  58. LEVY D
    The role of mEH, NTCP and OATP in hepatic sodium-dependent bile acid transport.
    Hepatology. 2017 Dec 6. doi: 10.1002/hep.29712.
    PubMed     Text format    


  59. BOWLUS CL
    Scratching the surface of cholestatic itch treatments.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29698.
    PubMed     Text format    


    November 2017
  60. ONO SK, Bassit L, Van Vaisberg V, Avancini Ferreira Alves V, et al
    Acute acalculous cholecystitis during Zika virus infection in an immunocompromised patient.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29682.
    PubMed     Text format    


  61. ORNOLFSSON KT, Olafsson S, Bergmann OM, Gershwin ME, et al
    Using the Icelandic Genealogical Database to define the familial risk of primary biliary cholangitis.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29675.
    PubMed     Text format     Abstract available


  62. HARTMANN P, Hochrath K, Horvath A, Chen P, et al
    Modulation of the intestinal bile acid-FXR-FGF15 axis improves alcoholic liver disease in mice.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29676.
    PubMed     Text format     Abstract available


  63. YOUNOSSI ZM, Afendy A, Stepanova M, Racila A, et al
    Development and Validation of a Primary Sclerosing Cholangitis-Specific Patient-Reported Outcomes Instrument: The PSC PRO.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29664.
    PubMed     Text format     Abstract available


  64. SHARMA A, Gandhi CR
    "CHOP"ing intestinal stem cells on way to cholestatic liver injury.
    Hepatology. 2017 Nov 16. doi: 10.1002/hep.29656.
    PubMed     Text format    


  65. AFONSO MB, Rodrigues CMP
    microRevolution in understanding primary biliary cholangitis pathophysiology.
    Hepatology. 2017 Nov 15. doi: 10.1002/hep.29653.
    PubMed     Text format    


  66. SCHRAMM C, Eaton J, Ringe KI, Venkatesh S, et al
    Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group.
    Hepatology. 2017;66:1675-1688.
    PubMed     Text format     Abstract available


  67. ELLIS JL, Bove KE, Schuetz EG, Leino D, et al
    Zebrafish abcb11b mutant reveals novel strategies to restore bile excretion impaired by bile salt export pump deficiency.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29632.
    PubMed     Text format     Abstract available


  68. CARBONE M, Bonato G, Invernizzi P
    Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29625.
    PubMed     Text format    


    October 2017
  69. JANSEN PLM
    Hydrodynamics of bile flow Lessons from computational modelling.
    Hepatology. 2017 Oct 27. doi: 10.1002/hep.29618.
    PubMed     Text format    


  70. LIASKOU E, Hirschfield GM
    Genetic association studies and the risk factors for developing the 'immuno-bile-logic' disease PBC.
    Hepatology. 2017 Oct 24. doi: 10.1002/hep.29603.
    PubMed     Text format    


  71. JALAN-SAKRIKAR N, Huebert RC
    Ducts in a Dish: Bioengineered Biliary Scaffolds for Regenerative Medicine.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29614.
    PubMed     Text format    


  72. EHRLICH L, Glaser SS
    Novel beta-catenin/FXR Interaction Regulates Hepatic Bile Acid Metabolism During Cholestasis.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29584.
    PubMed     Text format    


  73. KOWDLEY KV, Luketic V, Chapman R, Hirschfield GM, et al
    A Randomized Trial of Obeticholic Acid Monotherapy in Patients with Primary Biliary Cholangitis.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29569.
    PubMed     Text format     Abstract available


  74. FERANCHAK AP
    CFTR: Actin(g) as a master regulator of cholangiocyte function.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29583.
    PubMed     Text format    


  75. MASYUK AI, Masyuk TV, Lorenzo Pisarello MJ, Ding JF, et al
    Cholangiocyte Autophagy Contributes to Hepatic Cystogenesis in Polycystic Liver Disease and Represents a Potential Therapeutic Target.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29577.
    PubMed     Text format     Abstract available


  76. PRADHAN-SUNDD T, Zhou L, Vats R, Jiang A, et al
    Dual catenin loss in murine liver causes tight junctional deregulation and progressive intrahepatic cholestasis.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29585.
    PubMed     Text format     Abstract available


    September 2017
  77. LIU R, Li X, Huang Z, Zhao D, et al
    CHOP-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29540.
    PubMed     Text format     Abstract available


  78. JAHN D, Geier A
    Bile acids in NASH: pathophysiological driving force or innocent bystanders?
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29543.
    PubMed     Text format    


  79. ERICE O, Munoz-Garrido P, Vaquero J, Perugorria MJ, et al
    MiRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.
    Hepatology. 2017 Sep 18. doi: 10.1002/hep.29533.
    PubMed     Text format     Abstract available


  80. BAE HR, Hodge DL, Yang GX, Leung PSC, et al
    The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex-biased autoimmunity.
    Hepatology. 2017 Sep 16. doi: 10.1002/hep.29524.
    PubMed     Text format     Abstract available


  81. SULTAN M, Rao A, Elpeleg O, Vaz FM, et al
    Organic Solute Transporter-beta (SLC51B) Deficiency in Two Brothers with Congenital Diarrhea and Features of Cholestasis.
    Hepatology. 2017 Sep 12. doi: 10.1002/hep.29516.
    PubMed     Text format     Abstract available


  82. LUO Z, Jegga AG, Bezerra JA
    Gene-disease associations identify a connectome with shared molecular pathways in human cholangiopathies.
    Hepatology. 2017 Sep 2. doi: 10.1002/hep.29504.
    PubMed     Text format     Abstract available


  83. DELLAVANCE A, Ferraz MLG, Cancado ELR, Andrade LEC, et al
    Expansion and intensification of humoral autoimmune response in the transition from preclinical to full-blown primary biliary cholangitis.
    Hepatology. 2017;66:997.
    PubMed     Text format    


    August 2017
  84. VYAS D, Baptista PM, Brovold M, Moran E, et al
    Self-assembled liver organoids recapitulate hepato-biliary organogenesis in vitro.
    Hepatology. 2017 Aug 23. doi: 10.1002/hep.29483.
    PubMed     Text format     Abstract available


  85. DEMAREZ C, Gerard C, Cordi S, Poncy A, et al
    MiR-337-3p controls hepatobiliary gene expression and transcriptional dynamics during hepatic cell differentiation.
    Hepatology. 2017 Aug 17. doi: 10.1002/hep.29475.
    PubMed     Text format     Abstract available


  86. MONCSEK A, Al-Suraih MS, Trussoni CE, O'Hara SP, et al
    Targeting senescent cholangiocytes and activated fibroblasts with Bcl-xL inhibitors ameliorates fibrosis in Mdr2-/- mice.
    Hepatology. 2017 Aug 12. doi: 10.1002/hep.29464.
    PubMed     Text format     Abstract available


    July 2017
  87. GU J, Jeong S, Xia Q
    Intrahepatic cholangiocarcinoma arising from HBV Infection may be a highly selected population for liver transplantation.
    Hepatology. 2017 Jul 31. doi: 10.1002/hep.29413.
    PubMed     Text format    


  88. FIOROTTO R, Amenduni M, Mariotti V, Fabris L, et al
    Src kinase inhibition reduces inflammatory and cytoskeletal changes in DeltaF508 human cholangiocytes and improves CFTR correctors efficacy.
    Hepatology. 2017 Jul 24. doi: 10.1002/hep.29400.
    PubMed     Text format     Abstract available


  89. THOMPSON MD, Moghe A, Cornuet P, Marino R, et al
    beta-catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29371.
    PubMed     Text format     Abstract available


  90. PURI P, Daita K, Joyce A, Mirshahi F, et al
    The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
    Hepatology. 2017 Jul 11. doi: 10.1002/hep.29359.
    PubMed     Text format     Abstract available


  91. PELLAT A, Vaquero J, Fouassier L
    Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology.
    Hepatology. 2017 Jul 3. doi: 10.1002/hep.29350.
    PubMed     Text format     Abstract available


    June 2017
  92. WANG DQ, Portincasa P, Tso P
    Transintestinal cholesterol excretion (TICE): A secondary, non-biliary pathway contributing to reverse cholesterol transport.
    Hepatology. 2017 Jun 27. doi: 10.1002/hep.29341.
    PubMed     Text format    


  93. DAWSON PA
    Hepatic bile acid uptake in humans and mice: Multiple pathways and expanding potential role for gut-liver signaling.
    Hepatology. 2017 Jun 23. doi: 10.1002/hep.29325.
    PubMed     Text format    


  94. ALVARO D
    The challenge of cholangiocarcinoma diagnosis: the turning point is in extracellular vesicles?
    Hepatology. 2017 Jun 12. doi: 10.1002/hep.29314.
    PubMed     Text format    


  95. CHOI TY, Khaliq M, Tsurusaki S, Ninov N, et al
    Bmp Signaling Governs Biliary-Driven Liver Regeneration in Zebrafish via Tbx2b and Id2a.
    Hepatology. 2017 Jun 9. doi: 10.1002/hep.29309.
    PubMed     Text format     Abstract available


  96. LIBERAL R, Grant CR, Yuksel M, Graham J, et al
    Treg Conditioning Endows Activated Teff with Suppressor Function in Autoimmune Hepatitis/Autoimmune Sclerosing Cholangitis.
    Hepatology. 2017 Jun 9. doi: 10.1002/hep.29307.
    PubMed     Text format     Abstract available


  97. QIAN Y, Yao W, Yang T, Yang Y, et al
    aPKC-iota/P-Sp1/Snail signaling induces epithelial-mesenchymal transition and immunosuppression in cholangiocarcinoma.
    Hepatology. 2017 Jun 2. doi: 10.1002/hep.29296.
    PubMed     Text format     Abstract available


    May 2017
  98. ARBELAIZ A, Azkargorta M, Krawczyk M, Santos-Laso A, et al
    Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
    Hepatology. 2017 May 26. doi: 10.1002/hep.29291.
    PubMed     Text format     Abstract available


  99. CHIANG JYL
    Linking long non-coding RNA to control bile acid signaling and cholestatic liver fibrosis.
    Hepatology. 2017 May 24. doi: 10.1002/hep.29289.
    PubMed     Text format    


  100. TOMINAGA K, Kamimura K, Sakamaki A, Terai S, et al
    Intraductal Papillary Neoplasm of the Bile Duct: A Rare Liver Tumor Complicated by Malignancy.
    Hepatology. 2017 May 18. doi: 10.1002/hep.29266.
    PubMed     Text format    


  101. GUO GL
    Why are females more susceptible to cholestasis-induced liver injury - Could it be LncRNA H19?
    Hepatology. 2017 May 15. doi: 10.1002/hep.29255.
    PubMed     Text format    


  102. SLIJEPCEVIC D, Roscam Abbing RLP, Katafuchi T, Blank A, et al
    Hepatic uptake of conjugated bile acids is mediated by both NTCP and OATPs and modulated by intestinal sensing of plasma bile acid levels in mice.
    Hepatology. 2017 May 12. doi: 10.1002/hep.29251.
    PubMed     Text format     Abstract available


  103. TANAKA T, Zhang W, Sun Y, Shuai Z, et al
    Autoreactive Monoclonal Antibodies from Patients with Primary Biliary Cholangitis Recognize Environmental Xenobiotics.
    Hepatology. 2017 May 3. doi: 10.1002/hep.29245.
    PubMed     Text format     Abstract available


    April 2017
  104. SONG Y, Liu C, Liu X, Trottier J, et al
    H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of EpCAM.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29209.
    PubMed     Text format     Abstract available


  105. MIELI-VERGANI G, Vergani D
    The riddle of juvenile sclerosing cholangitis.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29208.
    PubMed     Text format    


  106. DENEAU MR, El-Matary W, Valentino PL, Abdou R, et al
    The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29204.
    PubMed     Text format     Abstract available


  107. LEVY C
    Primary biliary cholangitis: Treatment options finally expand.
    Hepatology. 2017;65:1405-1407.
    PubMed     Text format    


    March 2017
  108. LI X, Liu R, Yang J, Sun L, et al
    The role of LncRNA H19 in gender disparity of cholestatic liver injury in Mdr2-/- mice.
    Hepatology. 2017 Mar 8. doi: 10.1002/hep.29145.
    PubMed     Text format     Abstract available


  109. WAN Y, Meng F, Wu N, Zhou T, et al
    Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29138.
    PubMed     Text format     Abstract available


    February 2017
  110. LI H, Zhou ZQ, Yang ZR, Tong DN, et al
    MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.
    Hepatology. 2017 Feb 14. doi: 10.1002/hep.29116.
    PubMed     Text format     Abstract available


  111. KRAWCZYK M, Rau M, Grunhage F, Schattenberg JM, et al
    The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm.
    Hepatology. 2017 Feb 8. doi: 10.1002/hep.29100.
    PubMed     Text format    


    January 2017
  112. WANG Y, Aoki H, Yang J, Peng K, et al
    The role of S1PR2 in bile acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29076.
    PubMed     Text format     Abstract available


  113. HARGROVE L, Kennedy L, Demieville J, Jones H, et al
    BDL-induced biliary hyperplasia, hepatic injury and fibrosis are reduced in mast cell deficient Kitw-sh mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29079.
    PubMed     Text format     Abstract available


  114. SHUAI Z, Wang J, Badamagunta M, Choi J, et al
    The Fingerprint of Antimitochondrial Antibodies and the Etiology of Primary Biliary Cholangitis.
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29059.
    PubMed     Text format     Abstract available


  115. BJORNSSON ES, Jonasson JG
    Idiosyncratic drug-induced liver injury associated with bile duct loss and vanishing bile duct syndrome: Rare but has severe consequences.
    Hepatology. 2017 Jan 10. doi: 10.1002/hep.29040.
    PubMed     Text format    


  116. VIVEIROS A, Reiterer M, Schaefer B, Finkenstedt A, et al
    CCBE1 Mutation causing Sclerosing Cholangitis - Expanding the Spectrum of Lymphedema-Cholestasis Syndrome.
    Hepatology. 2017 Jan 10. doi: 10.1002/hep.29037.
    PubMed     Text format    


  117. MARONI L, Hohenester SD, van de Graaf SF, Tolenaars D, et al
    Knockout of the Primary Sclerosing Cholangitis-Risk Gene Fut2 Causes Liver Disease in Mice.
    Hepatology. 2017 Jan 5. doi: 10.1002/hep.29029.
    PubMed     Text format     Abstract available


    December 2016
  118. WANG KS, Tiao G, Bass LM, Hertel PM, et al
    Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29019.
    PubMed     Text format     Abstract available


  119. HAUSSINGER D, Keitel V
    Dual role of the bile acid receptor TGR5 for hepatic lipid metabolism in feast and famine.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29017.
    PubMed     Text format    


  120. QIU YL, Gong JY, Feng JY, Wang RX, et al
    Defects in MYO5B are associated with a spectrum of previously undiagnosed low gamma-glutamyltransferase cholestasis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29020.
    PubMed     Text format     Abstract available


  121. BRANDI G, De Lorenzo S, Palloni A, Biasco G, et al
    Aspirin for cholangiocarcinoma prevention: new targets to shift the dogma from ascertained risk to possible prevention (Reply to: Risk Factors for Cholangiocarcinoma: Aspirin-use and the Risk of Cholangiocarcinoma).
    Hepatology. 2016 Dec 23. doi: 10.1002/hep.28999.
    PubMed     Text format    


  122. TRAUNER M, Fuchs CD, Halilbasic E, Paumgartner G, et al
    New therapeutic concepts in bile acid transport and signaling for management of cholestasis.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28991.
    PubMed     Text format     Abstract available


  123. GUPTA R, Gupta J
    Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28994.
    PubMed     Text format    


  124. SAPISOCHIN G, Bruix J
    In response to: Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28993.
    PubMed     Text format    


  125. FAN W, Yang H, Liu T, Wang J, et al
    Prohibitin 1 Suppresses Liver Cancers Tumorigenesis in Mice and Human Hepatocellular and Cholangiocarcinoma cells.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28964.
    PubMed     Text format     Abstract available


  126. BONKOVSKY HL, Kleiner DE, Gu J, Odin JA, et al
    Clinical Presentations and Outcomes of Bile Duct Loss caused by Drugs and Herbal and Dietary Supplements.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28967.
    PubMed     Text format     Abstract available


  127. JANSEN PL, Ghallab A, Vartak N, Reif R, et al
    The ascending pathophysiology of cholestatic liver disease.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28965.
    PubMed     Text format     Abstract available


    November 2016
  128. DE VRIES EM, de Krijger M, Farkkila M, Arola J, et al
    Validation of the Prognostic Value of Histologic Scoring Systems in Primary Sclerosing Cholangitis; An International Cohort Study.
    Hepatology. 2016 Nov 23. doi: 10.1002/hep.28963.
    PubMed     Text format     Abstract available


  129. MOHANTY SK, Donnelly B, Lobeck I, Walther A, et al
    The SRL peptide of Rhesus Rotavirus VP4 protein governs cholangiocyte infection and the murine model of biliary atresia.
    Hepatology. 2016 Nov 17. doi: 10.1002/hep.28947.
    PubMed     Text format     Abstract available


  130. SAMUR S, Klebanoff M, Banken R, Pratt DS, et al
    Long-term Clinical Impact and Cost-Effectiveness of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis.
    Hepatology. 2016 Nov 7. doi: 10.1002/hep.28932.
    PubMed     Text format     Abstract available


  131. GRADILONE SA
    Extracellular vesicles as therapeutic carriers of microRNAs for cholangiocarcinoma.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28925.
    PubMed     Text format    


  132. ALTAII H, Al-Kindi SG, Oliveira GH, Yaqoob Z, et al
    Aspirin use and risk of cholangiocarcinoma: External validation with big data.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28920.
    PubMed     Text format    


  133. YAN S, Tang J, Zhang Y, Wang Y, et al
    Prostaglandin E2 promotes hepatic bile acid synthesis by an E prostanoid receptor 3-mediated hepatocyte nuclear receptor 4alpha/cholesterol 7alpha-hydroxylase pathway in mice.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28928.
    PubMed     Text format     Abstract available


    October 2016
  134. DESAI M, Mathur B, Eblimit Z, Vasquez H, et al
    Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28890.
    PubMed     Text format     Abstract available


  135. ZHANG L, Yang Z, Trottier J, Barbier O, et al
    LncRNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate Shp mRNA decay.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28882.
    PubMed     Text format     Abstract available


    September 2016
  136. DAHLQVIST G, Gaouar F, Carrat F, Meurisse S, et al
    Large-scale characterization study of patients with antimitochondrial antibodies but non-established primary biliary cholangitis.
    Hepatology. 2016 Sep 30. doi: 10.1002/hep.28859.
    PubMed     Text format     Abstract available


  137. LAGES CS, Simmons J, Maddox A, Jones K, et al
    The dendritic cell-Th17-macrophage axis controls cholangiocyte injury and disease progression in murine and human biliary atresia.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28851.
    PubMed     Text format     Abstract available


  138. KULKARNI SR, Soroka CJ, Hagey LR, Boyer JL, et al
    Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid fed mouse model of cholestasis.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28826.
    PubMed     Text format     Abstract available


  139. MCDANIEL K, Meng F, Wu N, Sato K, et al
    Forkhead box A2 regulated biliary heterogeneity and senescence during cholestatic liver injury.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28831.
    PubMed     Text format     Abstract available


  140. KAMINSKY P, Preiss J, Sasatomi E, Gerber DA, et al
    Biliary Adenofibroma: A Rare Hepatic Lesion with Malignant Features.
    Hepatology. 2016 Sep 15. doi: 10.1002/hep.28818.
    PubMed     Text format    


  141. FIOROTTO R, Villani A, Kourtidis A, Scirpo R, et al
    CFTR controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity.
    Hepatology. 2016 Sep 15. doi: 10.1002/hep.28817.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Biliary Tract Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: